CoChat

DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma

Li, Dongwei, Poon, Kirsten Achilles, Yu, Shang-Fan, Dere, Randall, Go, MaryAnn, Lau, Jeffrey, Zheng, Bing, Elkins, Kristi, Danilenko, Dimitry, Kozak, Katherine R., Chan, Pamela, Chuh, Josefa, Shi, Xiaoyan, Nazzal, Denise, Fuh, Franklin, McBride, Jacqueline, Ramakrishnan, Vanitha, de Tute, Ruth, Rawstron, Andy, Jack, Andrew S., Deng, Rong, Chu, Yu-Waye, Dornan, David, Williams, Marna, Ho, William, Ebens, Allen, Prabhu, Saileta, Polson, Andrew G. · 2013 · Molecular Cancer Therapeutics
Cited by 85

The DOI matches its Crossref record.

Abstract

Antibody–drug conjugates (ADC), potent cytotoxic drugs linked to antibodies via chemical linkers, allow specific targeting of drugs to neoplastic cells. We have used this technology to develop the ADC DCDT2980S that targets CD22, an antigen with expression limited to B cells and the vast majority of non-Hodgkin lymphomas (NHL). DCDT2980S consists of a humanized anti-CD22 monoclonal IgG1 antibody with a potent microtubule-disrupting agent, monomethyl auristatin E (MMAE), linked to the reduced cysteines of the antibody via a protease cleavable linker, maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl (MC-vc-PAB). We describe the efficacy, safety, and pharmacokinetics of DCDT2980S in animal models to assess its potential as a therapeutic for the treatment of B-cell malignancies. We did not find a strong correlation between in vitro or in vivo efficacy and CD22 surface expression, nor a correlation of sensitivity to free drug and in vitro potency. We show that DCDT2980S was capable of inducing complete tumor regression in xenograft mouse models of NHL and can be more effective than rituximab plus combination chemotherapy at drug exposures that were well tolerated in cynomolgus monkeys. These results suggest that DCDT2980S has an efficacy, safety, and pharmacokinetics profile that support potential treatment of NHL. Mol Cancer Ther; 12(7); 1255–65. ©2013 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-12-1173

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 85

Metadata

Authors
Li, D., Poon, K. A., Yu, S.-F., Dere, R., Go, M., Lau, J., Zheng, B., Elkins, K., Danilenko, D., Kozak, K. R., Chan, P., Chuh, J., Shi, X., Nazzal, D., Fuh, F., McBride, J., Ramakrishnan, V., de Tute, R., Rawstron, A., Jack, A. S., Deng, R., Chu, Y.-W., Dornan, D., Williams, M., Ho, W., Ebens, A., Prabhu, S., & Polson, A. G.
Venue
Molecular Cancer Therapeutics
Published
2013-07-01
Volume
12
Issue
7
Pages
1255-1265
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2158346246
Cited by
85
References
0
FWCI
8.08
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma. https://app.cochat.ai/papers/10.1158/1535-7163.mct-12-1173
The paper
Li, D., Poon, K. A., Yu, S.-F., Dere, R., Go, M., Lau, J., Zheng, B., Elkins, K., Danilenko, D., Kozak, K. R., Chan, P., Chuh, J., Shi, X., Nazzal, D., Fuh, F., McBride, J., Ramakrishnan, V., de Tute, R., Rawstron, A., . . . Polson, A. G. (2013). DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-12-1173

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.